254 related articles for article (PubMed ID: 23873253)
1. The effect of intravitreal bevacizumab injection as the initial treatment for Coats' disease.
Zheng XX; Jiang YR
Graefes Arch Clin Exp Ophthalmol; 2014 Jan; 252(1):35-42. PubMed ID: 23873253
[TBL] [Abstract][Full Text] [Related]
2. Bevacizumab for Coats' disease with exudative retinal detachment and risk of vitreoretinal traction.
Ramasubramanian A; Shields CL
Br J Ophthalmol; 2012 Mar; 96(3):356-9. PubMed ID: 21653215
[TBL] [Abstract][Full Text] [Related]
3. The efficacy of conbercept or ranibizumab intravitreal injection combined with laser therapy for Coats' disease.
Zhang L; Ke Y; Wang W; Shi X; Hei K; Li X
Graefes Arch Clin Exp Ophthalmol; 2018 Jul; 256(7):1339-1346. PubMed ID: 29549425
[TBL] [Abstract][Full Text] [Related]
4. Successful use of intravitreal bevacizumab and pascal laser photocoagulation in the management of adult Coats' disease.
Raoof N; Quhill F
Middle East Afr J Ophthalmol; 2013; 20(3):256-8. PubMed ID: 24014992
[TBL] [Abstract][Full Text] [Related]
5. Intravitreal bevacizumab injections combined with laser photocoagulation for adult-onset Coats' disease.
Park S; Cho HJ; Lee DW; Kim CG; Kim JW
Graefes Arch Clin Exp Ophthalmol; 2016 Aug; 254(8):1511-1517. PubMed ID: 26631136
[TBL] [Abstract][Full Text] [Related]
6. Combination treatment of pediatric coats' disease: a bicenter study in Taiwan.
Lin CJ; Chen SN; Hwang JF; Yang CM
J Pediatr Ophthalmol Strabismus; 2013; 50(6):356-62. PubMed ID: 24669373
[TBL] [Abstract][Full Text] [Related]
7. Successful use of intravitreal ranibizumab injection and combined treatment in the management of Coats' disease.
Yang Q; Wei W; Shi X; Yang L
Acta Ophthalmol; 2016 Jun; 94(4):401-6. PubMed ID: 27150442
[TBL] [Abstract][Full Text] [Related]
8. Use of intravitreal triamcinolone and bevacizumab in Coats' disease with central macular edema.
Böhm MR; Uhlig CE
Graefes Arch Clin Exp Ophthalmol; 2011 Jul; 249(7):1099-101. PubMed ID: 21318335
[TBL] [Abstract][Full Text] [Related]
9. Elevated vascular endothelial growth factor level in Coats' disease and possible therapeutic role of bevacizumab.
He YG; Wang H; Zhao B; Lee J; Bahl D; McCluskey J
Graefes Arch Clin Exp Ophthalmol; 2010 Oct; 248(10):1519-21. PubMed ID: 20379736
[TBL] [Abstract][Full Text] [Related]
10. A combination of intravitreal bevacizumab injection with tunable argon yellow laser photocoagulation as a treatment for adult-onset Coats' disease.
Wang KY; Cheng CK
J Ocul Pharmacol Ther; 2011 Oct; 27(5):525-30. PubMed ID: 21951171
[TBL] [Abstract][Full Text] [Related]
11. Role of intravitreal bevacizumab in adult onset Coats' disease.
Goel N; Kumar V; Seth A; Raina UK; Ghosh B
Int Ophthalmol; 2011 Jun; 31(3):183-90. PubMed ID: 21437759
[TBL] [Abstract][Full Text] [Related]
12. Use of intravitreal bevacizumab injections to treat type 1 idiopathic macular telangiectasia.
Moon BG; Kim YJ; Yoon YH; Lee JY
Graefes Arch Clin Exp Ophthalmol; 2012 Nov; 250(11):1697-9. PubMed ID: 21863255
[No Abstract] [Full Text] [Related]
13. Long term result of intravitreal bevacizumab in a patient newly transformed to proliferative macular telangiectasia type 2.
Ozkaya A; Alkin Z; Karakucuk Y; Yazici AT; Demirok A
Middle East Afr J Ophthalmol; 2013; 20(4):360-2. PubMed ID: 24339691
[TBL] [Abstract][Full Text] [Related]
14. Resolution of total retinal detachment in Coats' disease with intravitreal injection of bevacizumab.
Zhao T; Wang K; Ma Y; Jiang YR
Graefes Arch Clin Exp Ophthalmol; 2011 Nov; 249(11):1745-6. PubMed ID: 21080196
[No Abstract] [Full Text] [Related]
15. Treatment of Coats' disease with intravitreal bevacizumab.
Ray R; Barañano DE; Hubbard GB
Br J Ophthalmol; 2013 Mar; 97(3):272-7. PubMed ID: 23269680
[TBL] [Abstract][Full Text] [Related]
16. Combined treatment for Coats' disease: retinal laser photocoagulation combined with intravitreal bevacizumab injection was effective in two cases.
Kodama A; Sugioka K; Kusaka S; Matsumoto C; Shimomura Y
BMC Ophthalmol; 2014 Mar; 14():36. PubMed ID: 24666524
[TBL] [Abstract][Full Text] [Related]
17. Long-term efficacy and complications of intravitreal anti-vascular endothelial growth factor agents combined with ablative therapies in juvenile Coats disease: a five year follow-up study.
Li L; Li S; Liu J; Deng G; Ma J; Lu H
Graefes Arch Clin Exp Ophthalmol; 2024 Jan; 262(1):305-312. PubMed ID: 37421483
[TBL] [Abstract][Full Text] [Related]
18. Intravitreal bevacizumab for treatment of proliferative and nonproliferative type 2 idiopathic macular telangiectasia.
Roller AB; Folk JC; Patel NM; Boldt HC; Russell SR; Abramoff MD; Mahajan VB
Retina; 2011 Oct; 31(9):1848-55. PubMed ID: 21610563
[TBL] [Abstract][Full Text] [Related]
19. The effects of a treatment combination of anti-VEGF injections, laser coagulation and cryotherapy on patients with type 3 Coat's disease.
Li S; Deng G; Liu J; Ma Y; Lu H
BMC Ophthalmol; 2017 May; 17(1):76. PubMed ID: 28532448
[TBL] [Abstract][Full Text] [Related]
20. Resolution of macular edema in Coats' disease with intravitreal bevacizumab.
Entezari M; Ramezani A; Safavizadeh L; Bassirnia N
Indian J Ophthalmol; 2010; 58(1):80-2. PubMed ID: 20029156
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
